Sanofi (NASDAQ:SNY) saw a downside of -0.78% to close Tuesday at $48.30 after subtracting -$0.38 on the day. The 5-day average trading volume is 1,006,060 shares of the company’s common stock. It has gained $49.08 in the past week. An average of 1,750,730 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,144,754.
SNY’s 1-month performance is 0.21% or -$0.02 on its low of $47.55 reached on 09/20/21. The company’s shares have touched a 52-week low of $44.76 and high of $54.26, with the stock’s rally to the 52-week high happening on 06/14/21. YTD, SNY has lost -0.60% or -$0.29. However, the current price is down -10.98%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The company’s PE ratio for the last five years has touched a high of 41.13 and a low of 8.851. SNY stock has a beta of 0.58. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.79 while the price-to-book (PB) in the most recent quarter is 1.65.
Sanofi pays an annual dividend of $1.37 per share. Its dividend yield is 2.84%. SNY’s most recent quarterly dividend payment was made on May. 26, when it paid $1.9061 a share compared with prior rate of $1.2120, up 36.41% from last year’s. The company has boosted its dividend for the last 1 consecutive years with the latest dividend increase of $0.6941 reported on Thursday March 25 2021. Measured over the last 3 years, the Dividend has been growing by 3.58% yearly.
It is projected that Sanofi’s next ex-dividend date will be on 3-May. SNY is expected to distribute $1.828 as its next dividend.
Sanofi’s quick ratio for the period ended June 29 was 1.10, with the current ratio over the same period at 1.50 meaning that SNY stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.30, while the total debt to equity was 0.34. In terms of profitability, the gross margin trailing 12 months is 67.60%. The trailing 12-month EBITDA margin is 29.21%. The firm’s gross profit as reported stood at $28.8 billion against revenue of $42.69 billion.
For the quarterly period ending June 29 this year, Sanofi’s cash and short-term investments amounted to $1.39 billion against total debt of $21.65 billion. Net income shrunk -0.7% to $41.85 billion, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected SNY to announce $0.75 per share in earnings in its latest quarter, but it posted $0.83, representing a 10.70% surprise. SNY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 58.99 billion, with total debt at $21.65 billion
Let’s look briefly at Sanofi (SNY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 44.65% to suggest the stock is trending Neutral, with historical volatility in this time period at 10.59%.
The stock’s 5-day moving average is $48.56, reflecting a -0.04% or -$0.02 change from its current price. SNY is currently trading +0.04% above its 20-day SMA, -10.62% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -6.40% and +1.79% respectively.
Stochastic %K and %D was 72.35% and 76.31% and the average true range (ATR) pointed at 0.58. The RSI (14) points at 42.87%, while the 14-day stochastic is at 45.64% with the period’s ATR at 0.59. The stock’s 9-day MACD Oscillator is pointing at 0.26 and 0.33 on the 14-day charts.
In the most recent analyst report for Sanofi (NASDAQ: SNY), SVB Leerink upgraded it to an Outperform rating. They previously had a Mkt perform rating on the stock. Analysts offering their rating for SNY stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate SNY as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 15 have offered a “buy” rating.
What is SNY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $46.39 and a high of $70.59, with their median price target at $62.70. Looking at these predictions, the average price target given by analysts is for Sanofi (SNY) stock is $61.72.